bit.bio raises $103 million in first close of Series B financing
The funding will accelerate clinical development of cell therapies using breakthrough gene engineering technology opti-oxTM.
List view / Grid view
The funding will accelerate clinical development of cell therapies using breakthrough gene engineering technology opti-oxTM.
Researchers used obese fruit flies to analyse how gene activities affect triacylglyceride levels, unveiling novel drug targets for obesity.
The UK International Coronavirus Network (UK-ICN) aims to enhance knowledge of the virus family to prepare responses for future outbreaks.
The Gut Cell Atlas comprises 428,000 cells in the gut and sheds light on the origin of Crohn’s disease and other intestinal diseases.
Scientists unveiled how a DNA repair protein may prevent Huntington’s disease, presenting a new target in future therapies.
The RNA-modifying protein METTL1 could be targeted to treat some types of aggressive cancers, including brain, blood and kidney.
Scientists have shown that manipulating the perineuronal nets (PNNs) in the brains of mice led to the reversal of age-related memory loss.
Scientists have developed a “llama nanobody” that is capable of chasing out human cytomegalovirus (HCMV) so it is detected by the immune system.
An algorithm has been developed which can predict the outcomes of complex chemical reactions with over 90 percent accuracy which can be applied to drug development.
Researchers have used genome editing technology to reveal the role of a key gene in human embryos in the first few days of development...